InMed Pharmaceuticals to Merge with Mentari Therapeutics in All-Stock Deal, Secures $290M Financing

summarizeSummary

InMed Pharmaceuticals is merging with Mentari Therapeutics in an all-stock transaction, backed by a $290 million private placement, to pivot into migraine prevention therapies and secure long-term funding.

check_boxKey Events

• Transformative Merger Announced

  InMed Pharmaceuticals Inc. will merge with privately-held Mentari Therapeutics, Inc. in an all-stock transaction, with the combined entity operating as Mentari Therapeutics.

• Significant Capital Raise

  A concurrent oversubscribed private placement of $290 million is expected to fund the combined company's operations through 2028, addressing InMed's prior going concern issues.

• New Ownership Structure

  Pre-merger InMed shareholders are expected to own approximately 1.51% of the combined company, which will have a pro forma equity value of approximately $421.4 million.

• Focus on Migraine Prevention Pipeline

  The combined company will advance Mentari's pipeline of migraine prevention therapies, including MT-001 (anti-PACAP) and MT-002 (anti-CGRP x PACAP bispecific), with key clinical data expected by 2028 and 2027, respectively.

auto_awesomeAnalysis

InMed Pharmaceuticals is undergoing a transformative merger with privately-held Mentari Therapeutics, effectively becoming Mentari Therapeutics. This all-stock transaction includes a substantial $290 million concurrent private placement, which is expected to fund the combined company's operations through 2028. The deal addresses InMed's previously reported going concern doubt and short cash runway, providing a new strategic direction focused on migraine prevention therapies. While existing InMed shareholders will own approximately 1.51% of the combined entity, they will receive Contingent Value Rights (CVRs) representing 90% of net proceeds from the sale of InMed's pre-merger legacy assets. This event fundamentally alters the company's business, capital structure, and future prospects.